Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Arrowhead Pharmaceuticals, Inc.

Navigating SG&A Expenses in the Biotech Sector

In the dynamic world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, Bio-Techne Corporation and Arrowhead Pharmaceuticals, Inc. have demonstrated contrasting strategies in cost management. From 2014 to 2024, Bio-Techne's SG&A expenses surged by approximately 550%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Arrowhead Pharmaceuticals exhibited a more conservative growth of around 300% in the same period, indicating a strategic focus on lean operations.

Key Insights

• Bio-Techne Corporation: By 2024, Bio-Techne's SG&A expenses reached nearly four times that of 2014, highlighting its commitment to scaling operations.
• Arrowhead Pharmaceuticals, Inc.: Despite a significant increase, Arrowhead maintained a more measured approach, with expenses peaking in 2022.

These trends underscore the diverse approaches within the biotech industry, where strategic cost management can significantly impact a company's trajectory.